Cargando…
Persistent symptoms and lab abnormalities in patients who recovered from COVID-19
With increasing numbers of patients recovering from COVID-19, there is increasing evidence for persistent symptoms and the need for follow-up studies. This retrospective study included patients without comorbidities, who recovered from COVID-19 and attended an outpatient clinic at a university hospi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211641/ https://www.ncbi.nlm.nih.gov/pubmed/34140539 http://dx.doi.org/10.1038/s41598-021-91270-8 |
_version_ | 1783709507261562880 |
---|---|
author | Varghese, Julian Sandmann, Sarah Ochs, Kevin Schrempf, Inga-Marie Frömmel, Christopher Dugas, Martin Schmidt, Hartmut H. Vollenberg, Richard Tepasse, Phil-Robin |
author_facet | Varghese, Julian Sandmann, Sarah Ochs, Kevin Schrempf, Inga-Marie Frömmel, Christopher Dugas, Martin Schmidt, Hartmut H. Vollenberg, Richard Tepasse, Phil-Robin |
author_sort | Varghese, Julian |
collection | PubMed |
description | With increasing numbers of patients recovering from COVID-19, there is increasing evidence for persistent symptoms and the need for follow-up studies. This retrospective study included patients without comorbidities, who recovered from COVID-19 and attended an outpatient clinic at a university hospital for follow-up care and potential convalescent plasma donation. Network analysis was applied to visualize symptom combinations and persistent symptoms. Comprehensive lab-testing was ascertained at each follow-up to analyze differences regarding patients with vs without persistent symptoms. 116 patients were included, age range was 18–69 years (median: 41) with follow-ups ranging from 22 to 102 days. The three most frequent persistent symptoms were Fatigue (54%), Dyspnea (29%) and Anosmia (25%). Lymphopenia was present in 13 of 112 (12%) cases. Five of 35 cases (14%) had Lymphopenia in the later follow-up range of 80–102 days. Serum IgA concentration was the only lab parameter with significant difference between patients with vs without persistent symptoms with reduced serum IgA concentrations in the patient cohort of persistent symptoms (p = 0.0219). Moreover, subgroup analyses showed that patients with lymphopenia experienced more frequently persistent symptoms. In conclusion, lymphopenia persisted in a noticeable percentage of recovered patients. Patients with persistent symptoms had significantly lower serum IgA levels. Furthermore, our data provides evidence that lymphopenia is associated with persistence of COVID-19 symptoms. |
format | Online Article Text |
id | pubmed-8211641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82116412021-06-21 Persistent symptoms and lab abnormalities in patients who recovered from COVID-19 Varghese, Julian Sandmann, Sarah Ochs, Kevin Schrempf, Inga-Marie Frömmel, Christopher Dugas, Martin Schmidt, Hartmut H. Vollenberg, Richard Tepasse, Phil-Robin Sci Rep Article With increasing numbers of patients recovering from COVID-19, there is increasing evidence for persistent symptoms and the need for follow-up studies. This retrospective study included patients without comorbidities, who recovered from COVID-19 and attended an outpatient clinic at a university hospital for follow-up care and potential convalescent plasma donation. Network analysis was applied to visualize symptom combinations and persistent symptoms. Comprehensive lab-testing was ascertained at each follow-up to analyze differences regarding patients with vs without persistent symptoms. 116 patients were included, age range was 18–69 years (median: 41) with follow-ups ranging from 22 to 102 days. The three most frequent persistent symptoms were Fatigue (54%), Dyspnea (29%) and Anosmia (25%). Lymphopenia was present in 13 of 112 (12%) cases. Five of 35 cases (14%) had Lymphopenia in the later follow-up range of 80–102 days. Serum IgA concentration was the only lab parameter with significant difference between patients with vs without persistent symptoms with reduced serum IgA concentrations in the patient cohort of persistent symptoms (p = 0.0219). Moreover, subgroup analyses showed that patients with lymphopenia experienced more frequently persistent symptoms. In conclusion, lymphopenia persisted in a noticeable percentage of recovered patients. Patients with persistent symptoms had significantly lower serum IgA levels. Furthermore, our data provides evidence that lymphopenia is associated with persistence of COVID-19 symptoms. Nature Publishing Group UK 2021-06-17 /pmc/articles/PMC8211641/ /pubmed/34140539 http://dx.doi.org/10.1038/s41598-021-91270-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Varghese, Julian Sandmann, Sarah Ochs, Kevin Schrempf, Inga-Marie Frömmel, Christopher Dugas, Martin Schmidt, Hartmut H. Vollenberg, Richard Tepasse, Phil-Robin Persistent symptoms and lab abnormalities in patients who recovered from COVID-19 |
title | Persistent symptoms and lab abnormalities in patients who recovered from COVID-19 |
title_full | Persistent symptoms and lab abnormalities in patients who recovered from COVID-19 |
title_fullStr | Persistent symptoms and lab abnormalities in patients who recovered from COVID-19 |
title_full_unstemmed | Persistent symptoms and lab abnormalities in patients who recovered from COVID-19 |
title_short | Persistent symptoms and lab abnormalities in patients who recovered from COVID-19 |
title_sort | persistent symptoms and lab abnormalities in patients who recovered from covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211641/ https://www.ncbi.nlm.nih.gov/pubmed/34140539 http://dx.doi.org/10.1038/s41598-021-91270-8 |
work_keys_str_mv | AT varghesejulian persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT sandmannsarah persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT ochskevin persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT schrempfingamarie persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT frommelchristopher persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT dugasmartin persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT schmidthartmuth persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT vollenbergrichard persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT tepassephilrobin persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 |